U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk , from acquiring contract drug manufacturer Catalent ,

Five U.S. consumer groups and two big labor unions are pushing for the Federal Trade Commission to block Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT), arguing that a deal would hurt competition in weigh-loss drugs.

U.S. consumer groups and labor unions are urging the FTC to block Novo Holdings' acquisition of Catalent. They argue it could stifle competition for weight loss drugs and gene therapies, affecting companies like Amgen and Pfizer.

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,

The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in development of cell and gene therapies.

Consumer groups and labor unions urged the U.S. FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, warning it may stifle competition in weight loss drugs and gene therapies. Concerns include limited manufacturing options for GLP-1 rivals.